908 Devices Q1 2023 Earnings Report

908 Devices EPS Results

• Actual EPS: -$0.39
• Consensus EPS: -$0.35
• Beat/Miss: Missed by -$0.04
• One Year Ago EPS: -$0.30

908 Devices Revenue Results

• Actual Revenue: $9.50 million
• Expected Revenue: $8.65 million
• Beat/Miss: Beat by +$850.00 thousand
• YoY Revenue Growth: +14.50%

908 Devices Announcement Details

• Quarter: Q1 2023
• Date: 5/9/2023
• Time: Before Market Opens

908 Devices (NASDAQ:MASS), a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.